{"content":[{"text":"Under this agreement, Astellas will pay Ilypsa a total of US$ 92 million, including an \n upfront payment of US$ 22 million, as well as royalties in the mid-teen range on future \n sales of the drug in Japan. A Phase 1 clinical trial for Japan will be started during fiscal \n year 2006. Ilypsa has recently completed its Phase 1 clinical trial of ILY101 in the US and \n intends to initiate a Phase 2 study in chronic kidney disease patients with \n hyperphosphatemia within the next few months.","bbox":{"left":0.128625,"top":0.067938,"width":0.743084,"height":0.12440400000000001}},{"text":"About Astellas: \n Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to \n improving the health of people around the world through the provision of innovative and \n reliable pharmaceutical products. The organization is committed to becoming a global \n mega pharmaceutical company by combining outstanding R&D and marketing capabilities \n and continuing to grow in the world pharmaceutical market. For more information on \n Astellas Pharma Inc., please visit the company’s website at www.astellas.com.","bbox":{"left":0.128625,"top":0.215857,"width":0.7430430000000001,"height":0.145155}},{"text":"About Ilypsa: \n Ilypsa, Inc. is a privately held biopharmaceutical company discovering and developing a \n pipeline of next-generation renal care pharmaceutical products. Pioneering the use of a \n proprietary high throughput discovery and development platform created and validated at \n Symyx Technologies, Inc. (Nasdaq: SMMX), Ilypsa has rapidly created non-absorbed \n polymeric phosphate and potassium binder compounds to treat chronic kidney and \n metabolic diseases. To date, Ilypsa has raised $46 million in a Series A and a Series B \n round of financing. Investors include NLV Partners, 5AM Ventures, US Venture Partners, \n Johnson & Johnson Development Corporation and Delphi Ventures. For more information, \n please visit www.ilypsa.com.","bbox":{"left":0.128625,"top":0.384527,"width":0.743104,"height":0.20836100000000007}},{"text":"##### \n Ilypsa Contact: Astellas Contact: \n Gerrit Klaerner, Ph.D. Akihiro Tanaka, Ph.D. \n VP, Business and Corporate Development VP, Corporate Communications \n Tel.: +1-408-215-2826 Tel.: +81-3-3244-3201","bbox":{"left":0.128625,"top":0.617652,"width":0.644561,"height":0.10118800000000006}},{"text":"2","bbox":{"left":0.495144,"top":0.950431,"width":0.009807999999999983,"height":0.016634999999999955}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}